flow semaglutide trial kidney outcomes nejm 2024 hazard ratio 0.76 clinical (funded by Novo Nordisk) Patients with type 2 #diabetes

My goal is always to ensure that the product performs the same way from the first drop to the last, because consistency is what ultimately drives repeat purchases

doi: 10.1016/j.biopha.2018.08.088 18 MeierJJ

GLP-1 agents are not FDA-approved for anxiety or ADHD and lack dedicated clinical trials for these indications

For instance, liraglutide results in an average of 8% weight loss after 56 weeks, and tirzepatide can reduce body weight by as much as 21% in certain individuals

Adems, mantuvieron el peso que haban bajado seis meses despus

However, to date, the use of GLP1 receptorbased therapies has only been approved in the treatment of obesity and diabetes